DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...
National Glucose Awareness Week will take place from Sept. 23-29, 2024, and will encourage people to learn about the importance of glucose and its significant impact on overall health, especially for ...
Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness ...
Hosted on MSN
Listening to healthcare professionals: Dexcom launches new education offering, Dexcom Academy
DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning ...
Sourced from the diabetes community at large through an open call earlier this year, the 16 selected advocates represent strength, advocacy and pride in living with Type 1, Type 2 and prediabetes ...
At the conference, first-ever accuracy and performance data will be presented for Dexcom's upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making ...
DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results